v3.25.2
Fair Value Measurements
6 Months Ended 12 Months Ended
Jun. 30, 2025
Dec. 31, 2024
Fair Value Measurements  
3. Fair Value Measurements
A financial instrument’s level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. The Company did not have any financial instruments recorded at fair
 
value at December 31, 2024. The financial instruments measured at fair value on a recurring basis at December 31, 2023 in the accompanying consolidated balance sheets consist of the following (in thousands):
 
    
Fair value measurement as of December 31, 2023
 
    
Level 1
    
Level 2
    
Level 3
    
Total
 
Assets
           
Certificate of deposit
   $   
— 
     $ 10,151      $   —       $ 10,151  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total
   $ —       $ 10,151      $ —       $ 10,151  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There have been
no
transfers between fair value levels during the years ended December 31, 2024 and 2023.
IKENA ONCOLOGY INC    
Fair Value Measurements
3. Fair Value Measurements
The following tables present information about the Company’s
financial
assets measured or
disclosed
at fair value by level within the fair value hierarchy (in thousands):
 
    
June 30, 2025
    
Quoted Prices
in Active
Markets
(Level 1)
    
Significant
Observable
Inputs
(Level 2)
    
Significant
Unobservable
Inputs
(Level 3)
 
Cash equivalents:
           
Money market funds
   $ 34,334      $ 34,334      $ —       $ —   
Corporate debt securities
     2,399        —         2,399        —   
Marketable securities:
           
Corporate debt securities
     37,352        —         37,352        —   
  
 
 
    
 
 
    
 
 
    
 
 
 
Total assets
   $ 74,085      $ 34,334      $ 39,751      $ —   
  
 
 
    
 
 
    
 
 
    
 
 
 
 
    
December 31,
2024
    
Quoted Prices
in Active
Markets
(Level 1)
    
Significant
Observable
Inputs
(Level 2)
    
Significant
Unobservable
Inputs
(Level 3)
 
Cash equivalents:
           
Money market funds
   $ 34,793      $ 34,793      $ —       $ —   
Marketable securities:
           
U.S. treasury securities
     27,004        —         27,004        —   
Corporate debt securities
     57,989        —         57,989        —   
  
 
 
    
 
 
    
 
 
    
 
 
 
Total assets
   $ 119,786      $ 34,793      $ 84,993      $ —   
  
 
 
    
 
 
    
 
 
    
 
 
 
During the
three
and six months ended June 30, 2025 and 2024, there were no transfers into or out of Level 3.
3. FAIR VALUE MEASUREMENTS
The following tables present information about the Company’s financial assets measured or disclosed at fair value by level within the fair value hierarchy (in thousands):
 
    
December 31,
2024
    
Quoted
Prices in
Active
Markets
(Level 1)
    
Significant
Observable
Inputs
(Level 2)
    
Significant
Unobservable
Inputs
(Level 3)
 
Cash equivalents:
           
Money market funds
   $ 34,793      $ 34,793      $ —       $   —   
Marketable securities:
           
U.S. treasury securities
     27,004        —         27,004        —   
Corporate debt securities
     57,989        —         57,989        —   
  
 
 
    
 
 
    
 
 
    
 
 
 
Total assets
   $ 119,786      $ 34,793      $ 84,993      $ —   
  
 
 
    
 
 
    
 
 
    
 
 
 
 
    
December 31,
2023
    
Quoted
Prices in
Active
Markets
(Level 1)
    
Significant
Observable
Inputs
(Level 2)
    
Significant
Unobservable
Inputs
(Level 3)
 
Cash equivalents:
           
Money market funds
   $ 53,613      $ 53,613      $ —       $   —   
Marketable securities:
           
Corporate debt securities
     55,571        —         55,571        —   
  
 
 
    
 
 
    
 
 
    
 
 
 
Total assets
   $ 109,184      $ 53,613      $ 55,571      $ —   
  
 
 
    
 
 
    
 
 
    
 
 
 
During the years ended December 31, 2024 and 2023, there were no transfers into or out of Level 3.